New Blood Test Promises Earlier Liver Cancer Detection

Advances in diagnostic technologies are enhancing early liver cancer detection. Helio Genomics has developed a blood-based, multi-analyte approach that identifies tumor-associated epigenetic signals and protein biomarkers in circulating cell-free DNA. This non-invasive strategy offers earlier identification of cancer signals, even when conventional imaging is inconclusive.

A recent collaboration between Helio Genomics and Quest Diagnostics will make the HelioLiver test accessible through Quest's extensive US provider network. This integration into existing clinical pathways aims to reduce diagnostic delays and increase the proportion of patients diagnosed at a resectable stage.

Early detection is critical, as liver cancer outcomes are highly stage-dependent. Current screening methods have limitations in early-stage sensitivity. The improved diagnostic capabilities, combined with emerging immunotherapy-based perioperative treatments currently in late-stage trials, hold the potential to reshape the liver cancer treatment paradigm. This synergy could expand curative intervention eligibility and reduce recurrence risk, ultimately improving long-term patient outcomes.